Search Results - "Krop, Ian"

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial by Diéras, Véronique, Dr, Miles, David, Prof, Verma, Sunil, MD, Pegram, Mark, Prof, Welslau, Manfred, MD, Baselga, José, MD, Krop, Ian E, MD, Blackwell, Kim, Prof, Hoersch, Silke, MSc, Xu, Jin, PhD, Green, Marjorie, MD, Gianni, Luca, MD

“…Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer…”
Get full text

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial by Krop, Ian E, Dr, Kim, Sung-Bae, Prof, Martin, Antonio Gonzalez, MD, LoRusso, Patricia M, Prof, Ferrero, Jean-Marc, MD, Badovinac-Crnjevic, Tanja, MD, Hoersch, Silke, MSc, Smitt, Melanie, MD, Wildiers, Hans, Prof

“…Summary Background In the randomised, parallel assignment, open-label, phase 3 TH3RESA study, progression-free survival was significantly longer with…”
Get full text

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study by Modi, Shanu, Park, Haeseong, Murthy, Rashmi K, Iwata, Hiroji, Tamura, Kenji, Tsurutani, Junji, Moreno-Aspitia, Alvaro, Doi, Toshihiko, Sagara, Yasuaki, Redfern, Charles, Krop, Ian E, Lee, Caleb, Fujisaki, Yoshihiko, Sugihara, Masahiro, Zhang, Lin, Shahidi, Javad, Takahashi, Shunji

“…Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a…”
Get full text

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial by Krop, Ian E, Dr, Kim, Sung-Bae, Prof, González-Martín, Antonio, MD, LoRusso, Patricia M, Prof, Ferrero, Jean-Marc, Prof, Smitt, Melanie, MD, Yu, Ron, PhD, Leung, Abraham C F, MD, Wildiers, Hans, Prof

“…Summary Background Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective…”
Get full text

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes by Tung, Nadine M, Robson, Mark E, Ventz, Steffen, Santa-Maria, Cesar A, Nanda, Rita, Marcom, Paul K, Shah, Payal D, Ballinger, Tarah J, Yang, Eddy S, Vinayak, Shaveta, Melisko, Michelle, Brufsky, Adam, DeMeo, Michelle, Jenkins, Colby, Domchek, Susan, D'Andrea, Alan, Lin, Nancy U, Hughes, Melissa E, Carey, Lisa A, Wagle, Nick, Wulf, Gerburg M, Krop, Ian E, Wolff, Antonio C, Winer, Eric P, Garber, Judy E

“…Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-negative…”
Get full text

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study by Tamura, Kenji, Tsurutani, Junji, Takahashi, Shunji, Iwata, Hiroji, Krop, Ian E, Redfern, Charles, Sagara, Yasuaki, Doi, Toshihiko, Park, Haeseong, Murthy, Rashmi K, Redman, Rebecca A, Jikoh, Takahiro, Lee, Caleb, Sugihara, Masahiro, Shahidi, Javad, Yver, Antoine, Modi, Shanu

“…Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and…”
Get full text

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis by Barroso-Sousa, Romualdo, Barry, William T, Garrido-Castro, Ana C, Hodi, F Stephen, Min, Le, Krop, Ian E, Tolaney, Sara M

“…If not promptly recognized, endocrine dysfunction can be life threatening. The incidence and risk of developing such adverse events (AEs) following the use of…”
Get more information

CDK4/6 inhibition triggers anti-tumour immunity by Goel, Shom, DeCristo, Molly J., Watt, April C., BrinJones, Haley, Sceneay, Jaclyn, Li, Ben B., Khan, Naveed, Ubellacker, Jessalyn M., Xie, Shaozhen, Metzger-Filho, Otto, Hoog, Jeremy, Ellis, Matthew J., Ma, Cynthia X., Ramm, Susanne, Krop, Ian E., Winer, Eric P., Roberts, Thomas M., Kim, Hye-Jung, McAllister, Sandra S., Zhao, Jean J.

“…Mouse models of breast carcinoma and other solid tumours show that selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors not only induce tumour cell…”
Get full text

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer by Verma, Sunil, Miles, David, Gianni, Luca, Krop, Ian E, Welslau, Manfred, Baselga, José, Pegram, Mark, Oh, Do-Youn, Diéras, Véronique, Guardino, Ellie, Fang, Liang, Lu, Michael W, Olsen, Steven, Blackwell, Kim

“…Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to…”
Get full text

Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies by MAYER, Erica L, KROP, Ian E

“…Src, a membrane-associated nonreceptor tyrosine kinase, plays a crucial role in the coordination and facilitation of cell-signaling pathways controlling a wide…”
Get full text

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer by Barroso-Sousa, Romualdo, Keenan, Tanya E, Pernas, Sonia, Exman, Pedro, Jain, Esha, Garrido-Castro, Ana C, Hughes, Melissa, Bychkovsky, Brittany, Umeton, Renato, Files, Janet L, Lindeman, Neal I, MacConaill, Laura E, Hodi, F Stephen, Krop, Ian E, Dillon, Deborah, Winer, Eric P, Wagle, Nikhil, Lin, Nancy U, Mittendorf, Elizabeth A, Van Allen, Eliezer M, Tolaney, Sara M

“…Few patients with metastatic triple-negative breast cancer (mTNBC) benefit from immune checkpoint inhibitors (ICI). On the basis of immunotherapy response…”
Get full text

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial by Krop, Ian E, Dr, Mayer, Ingrid A, MD, Ganju, Vinod, FRACP, Dickler, Maura, MD, Johnston, Stephen, MD, Morales, Serafin, MD, Yardley, Denise A, MD, Melichar, Bohuslav, Prof, Forero-Torres, Andres, MD, Lee, Soo Chin, MRCP, de Boer, Richard, FRACP, Petrakova, Katarina, PhD, Vallentin, Susanne, MD, Perez, Edith A, MD, Piccart, Martine, Prof, Ellis, Matthew, Prof, Winer, Eric, Prof, Gendreau, Steven, PhD, Derynck, Mika, MD, Lackner, Mark, PhD, Levy, Gallia, MD, Qiu, Jiaheng, PhD, He, Jing, MD, Schmid, Peter, Prof

“…Summary Background Inhibition of phosphatidylinositol 3-kinase (PI3K) is a promising approach to overcome resistance to endocrine therapy in breast cancer…”
Get full text

Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer by KROP, Ian, WINER, Eric P

“…Trastuzumab emtansine (T-DM1) is a novel HER2-directed antibody-drug conjugate. T-DM1 consists of the potent antimicrotubule agent DM1, linked via a…”
Get full text

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update by Giordano, Sharon H, Temin, Sarah, Chandarlapaty, Sarat, Crews, Jennie R, Esteva, Francisco J, Kirshner, Jeffrey J, Krop, Ian E, Levinson, Jennifer, Lin, Nancy U, Modi, Shanu, Patt, Debra A, Perlmutter, Jane, Ramakrishna, Naren, Winer, Eric P, Davidson, Nancy E

“…Purpose To update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth…”
Get full text

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update by Ramakrishna, Naren, Anders, Carey K, Lin, Nancy U, Morikawa, Aki, Temin, Sarah, Chandarlapaty, Sarat, Crews, Jennie R, Davidson, Nancy E, Franzoi, Maria Alice B, Kirshner, Jeffrey J, Krop, Ian E, Patt, Debra A, Perlmutter, Jane, Giordano, Sharon H

“…To provide updated evidence- and consensus-based guideline recommendations to practicing oncologists and others on the management of brain metastases for…”
Get full text

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors by Goel, Shom, Wang, Qi, Watt, April C., Tolaney, Sara M., Dillon, Deborah A., Li, Wei, Ramm, Susanne, Palmer, Adam C., Yuzugullu, Haluk, Varadan, Vinay, Tuck, David, Harris, Lyndsay N., Wong, Kwok-Kin, Liu, X. Shirley, Sicinski, Piotr, Winer, Eric P., Krop, Ian E., Zhao, Jean J.

“…Using transgenic mouse models, cell line-based functional studies, and clinical specimens, we show that cyclin D1/CDK4 mediate resistance to targeted therapy…”
Get full text

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine by KROP, Ian E, LORUSSO, Patricia, AMLER, Lukas, WINER, Eric P, RUGO, Hope S, MILLER, Kathy D, MODI, Shanu, YARDLEY, Denise, RODRIGUEZ, Gladys, GUARDINO, Ellie, LU, Michael, MAOXIA ZHENG, GIRISH, Sandhya

“…To determine whether the antibody-drug conjugate trastuzumab emtansine (T-DM1), which combines human epidermal growth factor receptor 2 (HER2) -targeted…”
Get full text

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer by Tolaney, Sara M, Barry, William T, Dang, Chau T, Yardley, Denise A, Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S, Rugo, Hope S, Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C, Carey, Lisa A, Overmoyer, Beth A, Partridge, Ann H, Guo, Hao, Hudis, Clifford A, Krop, Ian E, Burstein, Harold J, Winer, Eric P

“…A multicenter single-group trial suggests that adjuvant therapy with paclitaxel plus trastuzumab lowers the risk of relapse in women with small HER2-positive…”
Get full text

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients by Tolaney, Sara M., Boucher, Yves, Duda, Dan G., Martin, John D., Seano, Giorgio, Ancukiewicz, Marek, Barry, William T., Goel, Shom, Lahdenrata, Johanna, Isakoff, Steven J., Yeh, Eren D., Jain, Saloni R., Golshan, Mehra, Brock, Jane, Snuderl, Matija, Winer, Eric P., Krop, Ian E., Jain, Rakesh K.

“…Preoperative bevacizumab and chemotherapy may benefit a subset of breast cancer (BC) patients. To explore potential mechanisms of this benefit, we conducted a…”
Get full text

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases by Freedman, Rachel A, Gelman, Rebecca S, Anders, Carey K, Melisko, Michelle E, Parsons, Heather A, Cropp, Anne M, Silvestri, Kelly, Cotter, Christine M, Componeschi, Kathryn P, Marte, Juan M, Connolly, Roisin M, Moy, Beverly, Van Poznak, Catherine H, Blackwell, Kimberly L, Puhalla, Shannon L, Jankowitz, Rachel C, Smith, Karen L, Ibrahim, Nuhad, Moynihan, Timothy J, O'Sullivan, Ciara C, Nangia, Julie, Niravath, Polly, Tung, Nadine, Pohlmann, Paula R, Burns, Robyn, Rimawi, Mothaffar F, Krop, Ian E, Wolff, Antonio C, Winer, Eric P, Lin, Nancy U

“…Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer to the CNS are limited. We previously reported…”
Get full text